Neulasta ("If Winter Comes" No. 24)
Went up to Seton NW this morning to get the Neulasta shot, its a $1000 shot that is tiny! It has proven to do the trick though (last time he had it)!
AJ felt fine all day and even after the shot, he took Propoxy (pain med) right afterwards just to see if it would be better this time to plan ahead with the pain medicine. Its now 22.30 and not doing too bad at all in regards of pain from Neulasta, just took two pills about 1 hour ago which should tie him over for about 6-8 hours. (He is not feeling pain yet)
The port is not so sore anymore, just a little bit tender.
AJ has a new great haircut, so now you can't even see that he is losing hair here and there. Its super short and he looks really hot :) :) :) ! Still eating great, taking all the vitamins and reds and greens. :)
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
